TWI811023B - 抗bcma抗體，結合bcma及cd3之雙特異性抗原結合分子及其用途 - Google Patents

抗bcma抗體，結合bcma及cd3之雙特異性抗原結合分子及其用途 Download PDF

Info

Publication number
TWI811023B
TWI811023B TW111126438A TW111126438A TWI811023B TW I811023 B TWI811023 B TW I811023B TW 111126438 A TW111126438 A TW 111126438A TW 111126438 A TW111126438 A TW 111126438A TW I811023 B TWI811023 B TW I811023B
Authority
TW
Taiwan
Prior art keywords
bcma
seq
antibody
antigen
heavy chain
Prior art date
Application number
TW111126438A
Other languages
English (en)
Chinese (zh)
Other versions
TW202307000A (zh
Inventor
庫丹達拉姆 皮拉瑞斯提
艾瑞克 鮑德溫
戈登 包爾斯
羅沙 卡多索
里卡多 阿塔爾
弗朗索瓦 高德特
Original Assignee
美商健生生物科技公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56740579&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI811023(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 美商健生生物科技公司 filed Critical 美商健生生物科技公司
Publication of TW202307000A publication Critical patent/TW202307000A/zh
Application granted granted Critical
Publication of TWI811023B publication Critical patent/TWI811023B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
TW111126438A 2015-08-17 2016-08-16 抗bcma抗體，結合bcma及cd3之雙特異性抗原結合分子及其用途 TWI811023B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562206246P 2015-08-17 2015-08-17
US62/206,246 2015-08-17

Publications (2)

Publication Number Publication Date
TW202307000A TW202307000A (zh) 2023-02-16
TWI811023B true TWI811023B (zh) 2023-08-01

Family

ID=56740579

Family Applications (3)

Application Number Title Priority Date Filing Date
TW105126031A TWI777924B (zh) 2015-08-17 2016-08-16 抗ｂｃｍａ抗體，結合ｂｃｍａ及ｃｄ３之雙特異性抗原結合分子及其用途
TW112124028A TW202406935A (zh) 2015-08-17 2016-08-16 抗bcma抗體，結合bcma及cd3之雙特異性抗原結合分子及其用途
TW111126438A TWI811023B (zh) 2015-08-17 2016-08-16 抗bcma抗體，結合bcma及cd3之雙特異性抗原結合分子及其用途

Family Applications Before (2)

Application Number Title Priority Date Filing Date
TW105126031A TWI777924B (zh) 2015-08-17 2016-08-16 抗ｂｃｍａ抗體，結合ｂｃｍａ及ｃｄ３之雙特異性抗原結合分子及其用途
TW112124028A TW202406935A (zh) 2015-08-17 2016-08-16 抗bcma抗體，結合bcma及cd3之雙特異性抗原結合分子及其用途

Country Status (41)

Country Link
US (1) US10072088B2 (enExample)
EP (3) EP4667058A2 (enExample)
JP (4) JP2018525005A (enExample)
KR (2) KR102890745B1 (enExample)
CN (1) CN108350076B (enExample)
AR (1) AR105724A1 (enExample)
AU (1) AU2016308567B2 (enExample)
BR (1) BR112018003017A2 (enExample)
CA (1) CA2995754A1 (enExample)
CL (1) CL2018000431A1 (enExample)
CO (1) CO2018001524A2 (enExample)
CY (2) CY1123297T1 (enExample)
DK (1) DK3337824T3 (enExample)
EA (1) EA201890513A1 (enExample)
EC (1) ECSP18019568A (enExample)
ES (1) ES2814550T3 (enExample)
FI (1) FIC20230012I1 (enExample)
FR (2) FR23C1011I1 (enExample)
HR (1) HRP20201375T1 (enExample)
HU (2) HUE050556T2 (enExample)
IL (3) IL298041B2 (enExample)
JO (1) JO3799B1 (enExample)
LT (2) LT3337824T (enExample)
LU (1) LUC00301I2 (enExample)
MA (1) MA53750A (enExample)
MX (2) MX2018002043A (enExample)
MY (1) MY191325A (enExample)
NI (1) NI201800027A (enExample)
NL (1) NL301219I2 (enExample)
PE (1) PE20180795A1 (enExample)
PH (1) PH12018500361A1 (enExample)
PL (1) PL3337824T3 (enExample)
PT (1) PT3337824T (enExample)
RS (1) RS60755B1 (enExample)
SI (1) SI3337824T1 (enExample)
SV (1) SV2018005634A (enExample)
TW (3) TWI777924B (enExample)
UA (1) UA127515C2 (enExample)
UY (1) UY36859A (enExample)
WO (1) WO2017031104A1 (enExample)
ZA (1) ZA201801789B (enExample)

Families Citing this family (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2954330A4 (en) 2013-02-08 2016-08-31 Inst Myeloma & Bone Cancer Res IMPROVED DIAGNOSTIC, PROGNOSTIC AND MONITORING METHODS FOR MULTIPLE MYELOMA, CHRONIC LYMPHOCYTIC LEUKEMIA AND NON-HODGKIN LYMPHOMA B-CELL LYMPHOMA
GB201317928D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Molecule
KR102612313B1 (ko) 2014-07-21 2023-12-12 노파르티스 아게 인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료
SG10202002131PA (en) 2015-05-21 2020-05-28 Harpoon Therapeutics Inc Trispecific binding proteins and methods of use
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
DK3402515T3 (da) 2016-01-12 2021-11-15 Oncotracker Inc Forbedrede fremgangsmåder til monitorering af et individs immunstatus
MY195542A (en) 2016-02-03 2023-01-31 Amgen Res Munich Gmbh Psma and CD3 Bispecific T Cell Engaging Antibody Constructs
CN108778329B (zh) 2016-02-17 2022-09-16 西雅图基因公司 Bcma抗体和其用以治疗癌症和免疫病症的用途
EP3455256A1 (en) * 2016-05-09 2019-03-20 Bristol-Myers Squibb Company Tl1a antibodies and uses thereof
AU2017268460B2 (en) 2016-05-20 2023-12-14 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
TWI781108B (zh) 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
SI4050034T1 (sl) 2016-09-14 2024-07-31 Teneoone, Inc. Protitelesa, ki se vežejo na CD3
BR112019012354A2 (pt) 2016-12-21 2019-11-26 Teneobio Inc anticorpos apenas de cadeia pesada anti-bcma
WO2018124766A2 (ko) 2016-12-28 2018-07-05 주식회사 녹십자랩셀 키메라 항원 수용체 및 이를 발현하는 자연 살해 세포
US20190375815A1 (en) 2017-01-31 2019-12-12 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2018209298A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Mesothelin binding proteins
WO2018231944A1 (en) 2017-06-13 2018-12-20 Berenson James R Diagnostic, prognostic, and monitoring methods for solid tumor cancers
IL312322A (en) 2017-06-20 2024-06-01 Teneobio Inc Anti-BCMA antibodies containing only heavy chains
MX2019015563A (es) * 2017-06-20 2020-07-28 Teneoone Inc Anticuerpos anti-bcma unicamente de cadena pesada.
WO2019000223A1 (en) * 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
IL312451A (en) * 2017-08-01 2024-06-01 Medimmune Llc Bcma monoclonal antibody-drug conjugate
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
CN111655280B (zh) * 2017-09-01 2025-01-14 达纳-法伯癌症研究所股份有限公司 用于治疗癌症的bcma和taci抗原特异的免疫原性肽
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
LT3694529T (lt) * 2017-10-13 2024-10-10 Harpoon Therapeutics, Inc. Trispecifiniai baltymai ir panaudojimo būdai
TW202428622A (zh) 2017-10-18 2024-07-16 瑞士商諾華公司 用於選擇性蛋白質降解的組合物及方法
PL3703750T3 (pl) 2017-11-01 2025-04-07 Juno Therapeutics, Inc. Chimeryczne receptory antygenowe specyficzne dla antygenu dojrzewania komórek b i kodujące polinukleotydy
CA3080904A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
WO2019090364A1 (en) 2017-11-06 2019-05-09 Juno Therapeutics, Inc. Combination of a cell therapy and a gamma secretase inhibitor
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
BR112020009336A2 (pt) 2017-11-15 2020-10-27 Novartis Ag receptor quimérico de antígenos de alvejamento de bcma, receptor quimérico de antígenos de alvejamento de cd19 e terapias de combinação
US20200371091A1 (en) 2017-11-30 2020-11-26 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
TW201930591A (zh) 2018-01-08 2019-08-01 瑞士商諾華公司 用於與嵌合抗原受體療法併用之免疫增強rna
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
EP3746116A1 (en) 2018-01-31 2020-12-09 Novartis AG Combination therapy using a chimeric antigen receptor
US20200399383A1 (en) 2018-02-13 2020-12-24 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2019190969A1 (en) * 2018-03-26 2019-10-03 Sutro Biopharma, Inc. Anti-bcma receptor antibodies, compositions comprising anti bcma receptor antibodies and methods of making and using anti-bcma antibodies
MX2020010728A (es) * 2018-04-13 2020-11-06 Affimed Gmbh Constructos de fusion de anticuerpos que se acoplan a celulas nk.
JP2021523192A (ja) 2018-05-14 2021-09-02 ハープーン セラピューティクス，インク． 免疫グロブリン分子の条件的活性化のための結合部分
EP3793606A4 (en) * 2018-05-16 2022-08-31 Janssen Biotech, Inc. METHODS OF TREATMENT OF CANCER AND ENHANCEMENT OF THE EFFECTIVENESS OF T-CELL REFERRING THERAPEUTICS
CN112384531B (zh) * 2018-06-01 2024-05-14 诺华股份有限公司 针对bcma的结合分子及其用途
EP3806962A1 (en) 2018-06-13 2021-04-21 Novartis AG Bcma chimeric antigen receptors and uses thereof
JP7357012B2 (ja) * 2018-06-14 2023-10-05 ２セブンティ バイオ インコーポレイテッド 抗ｂｃｍａ ｃａｒ抗体、コンジュゲート、および使用方法
KR102597053B1 (ko) 2018-06-26 2023-11-02 에이비엘바이오 주식회사 항-bcma 항체 및 그 용도
AU2019297451A1 (en) 2018-07-03 2021-01-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
JP7404335B2 (ja) 2018-07-19 2023-12-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｂｃｍａ特異性を有するキメラ抗原受容体およびその使用
TWI838389B (zh) * 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
TW202019477A (zh) * 2018-07-31 2020-06-01 德商安美基研究（慕尼黑）公司 BCMAxCD3抗體構建體之給藥方案
CA3108427A1 (en) * 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
EP3844267B1 (en) 2018-08-31 2025-06-25 Novartis AG Methods of making chimeric antigen receptor-expressing cells
EP3844265A2 (en) 2018-08-31 2021-07-07 Novartis AG Methods of making chimeric antigen receptor-expressing cells
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
WO2020073917A1 (en) 2018-10-09 2020-04-16 Single Cell Technology, Inc. Anti-bcma antibodies
AU2019370339B2 (en) * 2018-11-01 2024-07-11 Shandong New Time Pharmaceutical Co., Ltd. Bispecific antibody and use thereof
SG11202104188VA (en) 2018-11-01 2021-05-28 Juno Therapeutics Inc Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
EP3897720A4 (en) * 2018-12-19 2022-12-07 City of Hope BAFF-R BISPECIFIC T-LYMPHOCYTE ACTIVATING ANTIBODIES
EP3917964A1 (en) * 2019-02-01 2021-12-08 GlaxoSmithKline Intellectual Property Development Limited Combination treatments for cancer comprising belantamab mafodotin and an anti ox40 antibody and uses and methods thereof
CA3130754A1 (en) 2019-02-21 2020-08-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
WO2020172605A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
AU2020229806A1 (en) 2019-02-25 2021-07-29 Novartis Ag Mesoporous silica particles compositions for viral delivery
AU2020228367A1 (en) * 2019-02-26 2021-10-14 Vivasor, Inc. Antigen binding proteins that bind BCMA
EP3941938A1 (en) 2019-03-06 2022-01-26 Dana-Farber Cancer Institute, Inc. T cell receptors specific to b-cell maturation antigen for treatment of cancer
KR20210143246A (ko) 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
WO2020191316A1 (en) 2019-03-21 2020-09-24 Novartis Ag Car-t cell therapies with enhanced efficacy
CR20210500A (es) 2019-04-05 2021-11-05 Teneobio Inc Anticuerpos de cadena pesada que se unen al psma
WO2020210678A1 (en) 2019-04-12 2020-10-15 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2020219742A1 (en) 2019-04-24 2020-10-29 Novartis Ag Compositions and methods for selective protein degradation
EP3733707A1 (en) 2019-04-30 2020-11-04 Celyad S.A. Car t-cells targeting bcma and uses thereof
WO2020227110A1 (en) * 2019-05-03 2020-11-12 Sutro Biopharma, Inc. Anti-bcma antibody conjugate, compositions comprising the same, and methods of making and using the same
JOP20210309A1 (ar) 2019-05-21 2023-01-30 Novartis Ag جزيئات ربط بـ cd19 واستخدامتها
UA128906C2 (uk) 2019-06-14 2024-11-20 Тенеобіо, Інк. Поліспецифічні антитіла, що містять тільки важкі ланцюги, які зв'язуються з cd22 та cd3
CN111269315B (zh) * 2019-06-19 2022-04-08 北京智仁美博生物科技有限公司 针对bcma的单克隆抗体
AU2020322588A1 (en) * 2019-07-30 2022-02-03 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Anti-BCMA antibody, antigen-binding fragment thereof and medical use thereof
WO2021092060A1 (en) * 2019-11-05 2021-05-14 Engmab Sarl Methods of treatment
HRP20241281T1 (hr) 2019-11-11 2024-12-06 Amgen Research (Munich) Gmbh Režim doziranja anti-bcma sredstava
IL293215A (en) 2019-11-26 2022-07-01 Novartis Ag Chimeric antigen receptors that bind bcma and cd19 and their uses
CA3160352A1 (en) * 2019-12-06 2021-06-10 Israel Lowy Methods of treating multiple myeloma with bispecific anti-bcma x anti-cd3 antibodies
AU2020400801B2 (en) * 2019-12-10 2024-11-14 Abl Bio, Inc. Anti-BCMA/anti-4-1BB bispecific antibodies and uses thereof
WO2021132746A1 (en) * 2019-12-24 2021-07-01 Abl Bio, Inc. Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof
US20230030085A1 (en) * 2019-12-16 2023-02-02 2Seventy Bio, Inc. Anti-bcma car antibodies, conjugates, and methods of use
CN114981309B (zh) * 2020-01-03 2023-08-25 博奥信生物技术（南京）有限公司 结合bcma的抗体及其用途
GB2609554B (en) 2020-01-03 2025-08-20 Marengo Therapeutics Inc Anti-TCR antibody molecules and uses thereof
US20230256017A1 (en) 2020-02-27 2023-08-17 Jennifer Brogdon Methods of making chimeric antigen receptor-expressing cells
KR20220147109A (ko) 2020-02-27 2022-11-02 노파르티스 아게 키메라 항원 수용체 발현 세포의 제조 방법
WO2021183845A1 (en) * 2020-03-13 2021-09-16 Janssen Biotech, Inc. Materials and methods for modulating delta chain mediated immunity
TW202144425A (zh) * 2020-04-17 2021-12-01 大陸商上海翰森生物醫藥科技有限公司 特異性抗原結合分子，其製備方法及醫藥用途
CN115894703A (zh) * 2020-04-29 2023-04-04 特尼奥生物股份有限公司 具有经修饰重链恒定区的多特异性重链抗体
UY39191A (es) * 2020-04-29 2021-11-30 Teneobio Inc Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
CN113637073B (zh) * 2020-05-11 2024-04-12 上海赛比曼生物科技有限公司 Bcma抗体及其制备和应用
AU2021272291A1 (en) * 2020-05-11 2023-02-02 Janssen Biotech, Inc. Methods for treating multiple myeloma
TW202207977A (zh) 2020-05-19 2022-03-01 美商健生生物科技公司 包含ｔ細胞重導向治療劑及ｖｌａ－４黏附路徑抑制劑之組成物
CA3185455A1 (en) 2020-06-11 2021-12-16 Novartis Ag Zbtb32 inhibitors and uses thereof
KR20230015996A (ko) * 2020-06-30 2023-01-31 하버 바이오메드 (상하이) 컴퍼니 리미티드 H2l2 및 hcab 구조를 갖는 결합 단백질
PE20230464A1 (es) 2020-06-30 2023-03-14 Teneobio Inc Union de anticuerpos multiespecificos a bcma
CN114075287B (zh) * 2020-08-18 2023-07-21 湖南远泰生物技术有限公司 人源化bcma抗体和bcma-car-t细胞
WO2022040586A2 (en) 2020-08-21 2022-02-24 Novartis Ag Compositions and methods for in vivo generation of car expressing cells
BR112023003688A2 (pt) * 2020-09-14 2023-03-28 Pfizer Métodos, terapias e usos para tratar câncer
CN116829183A (zh) 2020-09-16 2023-09-29 美国安进公司 施用治疗剂量的双特异性t细胞接合分子治疗癌症的方法
US20240002539A1 (en) * 2020-11-03 2024-01-04 Ab Studio Inc. Multispecific antibodies and uses thereof
JP2023549780A (ja) 2020-11-04 2023-11-29 ジュノー セラピューティクス インコーポレイテッド 改変されたインバリアントｃｄ３免疫グロブリンスーパーファミリー鎖遺伝子座からキメラ受容体を発現する細胞ならびに関連するポリヌクレオチドおよび方法
CN118878694A (zh) * 2020-11-23 2024-11-01 康诺亚生物医药科技（成都）有限公司 一种双特异性抗体及其用途
CN114573703A (zh) * 2020-12-02 2022-06-03 康诺亚生物医药科技（成都）有限公司 一种t细胞衔接器治疗剂的开发和应用
WO2022135468A1 (zh) * 2020-12-23 2022-06-30 信达生物制药(苏州)有限公司 抗bcma×cd3双特异性抗体及其用途
HUE071594T2 (hu) 2021-01-28 2025-09-28 Regeneron Pharma Készítmények és módszerek a citokinfelszabadulási szindróma kezelésére
IL305144A (en) 2021-02-16 2023-10-01 Janssen Pharmaceutica Nv Trispecific antibodies targeting BCMA, GPRC5D and CD3
US12162945B2 (en) 2021-03-05 2024-12-10 Immunome, Inc. EPHA2 antibodies
EP4314070A1 (en) 2021-03-24 2024-02-07 Janssen Biotech, Inc. Trispecific antibody targeting cd79b, cd20, and cd3
CA3214757A1 (en) 2021-04-08 2022-10-13 Andreas Loew Multifuntional molecules binding to tcr and uses thereof
AR125468A1 (es) 2021-04-27 2023-07-19 Novartis Ag Sistema de producción de vectores virales
US11931420B2 (en) 2021-04-30 2024-03-19 Celgene Corporation Combination therapies using an anti-BCMA antibody drug conjugate (ADC) in combination with a gamma secretase inhibitor (GSI)
TW202309522A (zh) 2021-05-11 2023-03-01 美商健生生物科技公司 用於監測復發性及／或難治性多發性骨髓瘤之治療的方法及組成物
BR112023024822A2 (pt) 2021-05-28 2024-02-20 Acad Medisch Ct Bcma como alvo para anticorpos de redirecionamento de células t em linfomas de células b
CN119569887A (zh) * 2021-06-24 2025-03-07 益科思特(北京)医药科技发展有限公司 结合bcma和cd3的双特异性抗体及其制备方法与应用
CN115569191A (zh) * 2021-07-05 2023-01-06 山东新时代药业有限公司 一种重组人源化抗bcma/cd3双特异性抗体冻干制剂
WO2023020474A1 (en) * 2021-08-16 2023-02-23 Utc Therapeutics (Shanghai) Co., Ltd. Bcma targetting antibodies and uses thereof in cancer therapies
CN117858901A (zh) 2021-08-20 2024-04-09 诺华股份有限公司 制备表达嵌合抗原受体的细胞的方法
PE20241173A1 (es) 2021-10-14 2024-05-28 Arsenal Biosciences Inc Celulas inmunitarias que tienen arnhc coexpresados y sistemas de compuerta logica
EP4423141A4 (en) * 2021-10-27 2025-12-17 Janssen Biotech Inc METHOD FOR IMPROVED BCMA IMMUNOHISTOCHEMIC DETECTION IN HUMAN AND APE TISSUE
IL312503A (en) 2021-11-03 2024-07-01 Janssen Biotech Inc Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
CA3237175A1 (en) 2021-11-03 2023-05-11 Janssen Biotech, Inc. Corticosteriod reduction in treatment with anti-cd38 antibodies
KR20240099432A (ko) * 2021-11-10 2024-06-28 얀센 바이오테크 인코포레이티드 이중특이성 bcma/cd3 항체를 포함하는 안정한 제형
US20250026844A1 (en) * 2021-12-03 2025-01-23 Shandong Simcere Biopharmaceutical Co., Ltd. Anti-bcma nanobody and use thereof
KR20250004700A (ko) 2022-04-11 2025-01-08 리제너론 파마슈티칼스 인코포레이티드 보편적 종양 세포 사멸을 위한 조성물 및 방법
CN117003871A (zh) 2022-04-28 2023-11-07 北京天广实生物技术股份有限公司 结合bcma和cd3的抗体及其用途
CN116023504B (zh) * 2022-06-07 2025-09-30 江苏蒙彼利生物科技有限公司 双特异性嵌合抗原受体（car）及其制备方法
WO2024089639A1 (en) 2022-10-26 2024-05-02 Novartis Ag Lentiviral formulations
KR20250097946A (ko) 2022-11-02 2025-06-30 얀센 바이오테크 인코포레이티드 암을 치료하는 방법
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
WO2024119126A1 (en) * 2022-12-02 2024-06-06 Artiva Biotherapeutics, Inc. Anti-bcma antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
CN117186228B (zh) * 2022-12-06 2024-03-22 成都赛恩吉诺生物科技有限公司 包含长cdr3序列的抗人bcma纳米抗体的双特异性抗体及应用
WO2024124088A1 (en) * 2022-12-09 2024-06-13 Sana Biotechnology, Inc. Bcma-specific antibody constructs and compositions thereof
AU2024223918A1 (en) 2023-02-17 2025-09-11 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies
TW202440636A (zh) 2023-03-21 2024-10-16 美商傳記５５有限公司 Ｃｄ１９／ｃｄ３８多特異性抗體
US20250242019A2 (en) * 2023-04-19 2025-07-31 Janssen Biotech, Inc. Methods for treating multiple myeloma
US20240400702A1 (en) 2023-05-09 2024-12-05 Janssen Biotech, Inc. Pharmaceutical compositions comprising a bispecific bcma/cd3 antibody at high concentration
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
AU2024283895A1 (en) 2023-06-06 2025-12-18 Fortvita Biologics Inc. Preparation and use of anti-gprc5d/bcma/cd3 trispecific antibody
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025094107A1 (en) 2023-11-01 2025-05-08 Janssen Biotech, Inc. Methods for treating high-risk smoldering multiple myeloma
WO2025096717A1 (en) * 2023-11-01 2025-05-08 Janssen Biotech, Inc. Methods for treating multiple myeloma
WO2025131075A1 (zh) * 2023-12-21 2025-06-26 上海君实生物医药科技股份有限公司 抗cd3和抗cd3多特异性抗体及用途
US20250242018A1 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025160324A2 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
US20250276092A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025231372A2 (en) 2024-05-03 2025-11-06 Janssen Biotech, Inc. Methods for treating multiple myeloma with car-t cells and bispecific antibodies
WO2025243241A1 (en) 2024-05-23 2025-11-27 Janssen Biotech, Inc. Methods for treating multiple myeloma

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012158818A2 (en) * 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
TW201326214A (zh) * 2011-11-15 2013-07-01 Amgen Res Munich Gmbh Ｂｃｍａ及ｃｄ３結合分子

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1538206E (pt) 1997-09-16 2010-04-12 Centocor Ortho Biotech Inc Método para a síntese química e construção completa de genes e genomas
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
US20020142000A1 (en) 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
WO2001024812A1 (en) 1999-10-06 2001-04-12 N.V. Nutricia USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA
JP2004533997A (ja) 2001-02-20 2004-11-11 ザイモジェネティクス，インコーポレイティド Ｂｃｍａ及びｔａｃｉの両者を結合する抗体
US20060204493A1 (en) 2004-09-02 2006-09-14 Genentech, Inc. Heteromultimeric molecules
EP3623473A1 (en) 2005-03-31 2020-03-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
ES2616316T3 (es) 2005-10-11 2017-06-12 Amgen Research (Munich) Gmbh Composiciones que comprenden anticuerpos específicos para diferentes especies y usos de los mismos
EP1973576B1 (en) 2005-11-28 2019-05-15 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
WO2007117600A2 (en) 2006-04-07 2007-10-18 Macrogenics, Inc. Combination therapy for treating autoimmune diseases
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
CA2682626A1 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific bispecific binders
PT2520590T (pt) 2007-04-03 2018-11-14 Amgen Res Munich Gmbh Domínio de ligação específico de espécies cruzadas
RS53008B2 (sr) 2007-04-03 2022-12-30 Amgen Res Munich Gmbh Interspecijski specifičan cd3-epsilon vezujući domen
WO2009132058A2 (en) 2008-04-25 2009-10-29 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
CA2738566C (en) 2008-10-01 2024-04-30 Micromet Ag Bispecific single chain antibodies with specificity for high molecular weight target antigens
WO2010037836A2 (en) 2008-10-01 2010-04-08 Micromet Ag Cross-species-specific psmaxcd3 bispecific single chain antibody
EP2352765B1 (en) 2008-10-01 2018-01-03 Amgen Research (Munich) GmbH Cross-species-specific single domain bispecific single chain antibody
WO2010051274A2 (en) 2008-10-31 2010-05-06 Centocor Ortho Biotech Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
WO2010093627A2 (en) 2009-02-12 2010-08-19 Centocor Ortho Biotech Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
DK2406284T5 (en) 2009-03-10 2017-06-12 Biogen Ma Inc ANTI-BCMA ANTIBODIES
ES2708124T3 (es) 2009-04-27 2019-04-08 Oncomed Pharm Inc Procedimiento para preparar moléculas heteromultiméricas
JP6040148B2 (ja) 2010-04-20 2016-12-07 ゲンマブ エー／エス ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法
MX352929B (es) 2010-11-05 2017-12-13 Zymeworks Inc DISEÑO DE ANTICUERPOS HETERODIMÉRICOS ESTABLES CON MUTACIONES EN EL DOMINIO Fc.
EP2640750A1 (en) 2010-11-16 2013-09-25 Boehringer Ingelheim International GmbH Agents and methods for treating diseases that correlate with bcma expression
US20130101599A1 (en) 2011-04-21 2013-04-25 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
EP2739312B1 (en) * 2011-08-03 2017-10-04 Children's Medical Center Corporation A broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza hemagglutinin
KR102052774B1 (ko) 2011-11-04 2019-12-04 자임워크스 인코포레이티드 Ｆｃ 도메인 내의 돌연변이를 갖는 안정한 이종이합체 항체 설계
ES2963516T3 (es) 2012-12-14 2024-03-27 Omniab Inc Polinucleótidos que codifican anticuerpos de roedores con idiotipos humanos y animales que los contienen
EP2762497A1 (en) * 2013-02-05 2014-08-06 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3620468A1 (en) 2013-02-05 2020-03-11 EngMab Sàrl Method for the selection of antibodies against bcma

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012158818A2 (en) * 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
TW201326214A (zh) * 2011-11-15 2013-07-01 Amgen Res Munich Gmbh Ｂｃｍａ及ｃｄ３結合分子

Also Published As

Publication number Publication date
LTPA2023509I1 (enExample) 2023-03-10
JP2023027228A (ja) 2023-03-01
TWI777924B (zh) 2022-09-21
JP2018525005A (ja) 2018-09-06
HUS2300011I1 (hu) 2023-03-28
IL298041B1 (en) 2025-06-01
AU2016308567A1 (en) 2018-03-08
LTC3337824I2 (enExample) 2024-10-25
UY36859A (es) 2017-04-28
EP3757131A1 (en) 2020-12-30
CY2023007I2 (el) 2023-11-15
ES2814550T3 (es) 2021-03-29
FIC20230012I1 (fi) 2023-02-22
IL320478A (en) 2025-06-01
JP2021184721A (ja) 2021-12-09
WO2017031104A1 (en) 2017-02-23
SV2018005634A (es) 2018-06-26
IL298041A (en) 2023-01-01
IL298041B2 (en) 2025-10-01
CN108350076B (zh) 2022-06-07
KR20180040671A (ko) 2018-04-20
AU2016308567B2 (en) 2022-10-27
US20170051068A1 (en) 2017-02-23
LUC00301I2 (enExample) 2025-09-22
CO2018001524A2 (es) 2018-07-10
RS60755B1 (sr) 2020-10-30
NZ739862A (en) 2025-05-02
KR102890745B1 (ko) 2025-11-26
IL257468A (en) 2018-04-30
CA2995754A1 (en) 2017-02-23
PT3337824T (pt) 2020-09-10
JO3799B1 (ar) 2021-01-31
CL2018000431A1 (es) 2018-11-23
PH12018500361A1 (en) 2018-09-03
MA53750A (fr) 2021-09-15
TW201718651A (zh) 2017-06-01
JP7194240B2 (ja) 2022-12-21
JP7621324B2 (ja) 2025-01-24
EP3337824B1 (en) 2020-06-03
PE20180795A1 (es) 2018-05-09
EP3337824A1 (en) 2018-06-27
MX2018002043A (es) 2018-07-06
NL301219I2 (nl) 2023-04-04
SI3337824T1 (sl) 2020-10-30
LT3337824T (lt) 2020-09-25
BR112018003017A2 (pt) 2018-09-25
CY1123297T1 (el) 2021-12-31
ZA201801789B (en) 2019-10-30
KR20250007058A (ko) 2025-01-13
CN108350076A (zh) 2018-07-31
JP2025013894A (ja) 2025-01-28
FR23C1012I2 (fr) 2025-01-10
IL257468B2 (en) 2023-06-01
TW202307000A (zh) 2023-02-16
EA201890513A1 (ru) 2018-11-30
HRP20201375T1 (hr) 2020-11-27
EP4667058A2 (en) 2025-12-24
MY191325A (en) 2022-06-15
UA127515C2 (uk) 2023-09-20
NL301219I1 (enExample) 2023-03-01
DK3337824T3 (da) 2020-08-24
NI201800027A (es) 2018-08-30
PL3337824T3 (pl) 2021-04-19
FR23C1011I1 (fr) 2023-04-14
HUE050556T2 (hu) 2020-12-28
AR105724A1 (es) 2017-11-01
FR23C1012I1 (fr) 2023-04-14
ECSP18019568A (es) 2018-04-30
CY2023007I1 (el) 2023-06-09
TW202406935A (zh) 2024-02-16
US10072088B2 (en) 2018-09-11
MX2022006650A (es) 2022-07-05

Similar Documents

Publication Publication Date Title
JP7194240B2 (ja) 抗ｂｃｍａ抗体、ｂｃｍａ及びｃｄ３に結合する二重特異性抗原結合分子、並びにそれらの使用
TWI781108B (zh) 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
JP2024507180A (ja) Ｂｃｍａ、ｇｐｒｃ５ｄ、及びｃｄ３を標的とする三重特異的抗体
EP3371220A2 (en) Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof
TW202304988A (zh) 靶向ＣＤ７９ｂ、ＣＤ２０、及ＣＤ３之三特異性抗體
US20210269525A1 (en) ANTI-CD3e ANTIBODIES AND USES THEREOF
EA046105B1 (ru) Антитела к bcma, биспецифические антигенсвязывающие молекулы, которые связываются с bcma и cd3, и их применение
BR122025011670A2 (pt) Anticorpos anti-bcma, moléculas de ligação ao antígeno biespecíficas que se ligam a bcma e cd3, e usos dos mesmos
EA044685B1 (ru) Антитела к gprc5d, биспецифические антигенсвязывающие молекулы, которые связывают gprc5d и cd3, и их применение